Skip to navigation Skip to content

Gastrointestinal stromal tumour Program in Pharmaceutical Benefits Scheme (PBS) 012-18053000

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour (GIST).

GIST and listing dates

Gastrointestinal stromal tumour is a type of tumour occurring in the gastrointestinal tract, most commonly in the stomach or small intestine.

Listing dates are:

  • imatinib - 1 February 2004 - Metastatic/Unresectable
  • sunitinib - 1 December 2009
  • imatinib - 1 September 2011 - Adjuvant
  • ripretinib - 1 December 2021 - Metastatic/Unresectable

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • FAQs from Service Officers
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs